Click for contact details

News

10th December 2013
eZono 4000 with needle guidance approved in Europe
eZono 4000 with needle guidance approved in Europe
Read this article

2nd October 2013
Xention partners its lead atrial fibrillation drug with Servier
Xention and Servier announce a cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treatment of atrial fibrillation
Read this article

6th June 2013
Alliance Pharma acquires global rights to Syntometrine from Novartis
Alliance Pharma plc has acquired all existing rights to SyntometrineTM from Novartis AG and Novartis Pharma AG (together "Novartis") for a consideration of US$11.5 million.
Read this article

7th May 2013
Graham Cox to join eZono as CEO
eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.
Read this article

29th April 2013
Cara partners with Maruishi for Japanese rights to CR845
Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.
Read this article

News Archive
Last 5 Articles | Next 5 Articles

Article image
 9th May 2011
Heptares Grants Shire an Exclusive Option to License Novel Adenosine A2a Antagonist

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2a antagonist discovered by Heptares and currently in preclinical development. Adenosine A2a is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Recently, inhibition of the A2a receptor has been proved to be clinically effective in treating symptoms of Parkinson’s disease and may offer benefits in additional CNS diseases.

The Heptares A2a programme reflects a new approach to this GPCR target. Heptares stabilised the A2a receptor using its proprietary StaR® technology, determined the receptor’s binding characteristics through Biophysical Mapping™, and resolved its 3D crystal structure using x-ray crystallography. This advanced knowledge of the target enabled Heptares scientists to discover entirely new types of chemical structures for inhibiting the A2a receptor.

Under the terms of the agreement, Heptares has granted Shire an exclusive option, upon completion of certain preclinical studies, to license worldwide development and commercial rights to the Heptares A2a programme. Heptares has received an upfront payment and is eligible, upon exercise of the option by Shire, to an option exercise payment, future milestone payments, plus royalties on product sales. Further terms of the agreement are not being disclosed.

“We are excited to sign this option agreement with Shire for the development of our novel A2a antagonist, a potentially best-in-class new agent for treating patients suffering from debilitating CNS diseases,” said Malcolm Weir, CEO of Heptares. “A2a is an important and clinically validated GPCR drug target, yet it has never been adequately addressed by the available older chemistries. Heptares has discovered fundamentally novel chemotypes as the basis for a new and, we believe, superior approach to A2a receptor pharmacology.”

Associated Links
Visit Heptares Therapeutics Limited
Visit Shire Pharmaceuticals
Downloads
Full Press Release